Biomarker and Genetic Predictors of Erenumab Treatment Response
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Migraine
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 99 years
- Gender
- Both males and females
Description
This is a phase 4 open-label study aiming to explore the relationship between clinical response to erenumab and genetic biomarkers. Subjects with episodic or chronic migraine will be treated with Erenumab 70mg or 140mg for a 4-week baseline/screening period, followed by a 24-week treatment period. S...
This is a phase 4 open-label study aiming to explore the relationship between clinical response to erenumab and genetic biomarkers. Subjects with episodic or chronic migraine will be treated with Erenumab 70mg or 140mg for a 4-week baseline/screening period, followed by a 24-week treatment period. Subjects will collect migraine-related parameters daily using an eDiary and blood samples will be collected for biomarker research. All analysis will be descriptive in nature.
Tracking Information
- NCT #
- NCT04265755
- Collaborators
- Not Provided
- Investigators
- Study Director: MD Amgen